Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: A Children's Cancer Group study

Blood

Volumn 106, Issue 13, 2005, Pages 4043-4049

  Whitlock, James A ^b   Sather, Harland N ^b   Gaynon, Paul ^b   Robison, Leslie L ^b   Wells, Robert J ^b   Trigg, Michael ^b   Heerema, Nyla A ^b   Bhatia, Smita ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CLINICAL FEATURE; COMPARATIVE STUDY; CORRELATION ANALYSIS; DOWN SYNDROME; HIGH RISK PATIENT; HUMAN; HUMAN CELL; INFANT; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; NEWBORN; PRIORITY JOURNAL; RISK FACTOR; TIME SERIES ANALYSIS; TREATMENT OUTCOME;

EID: 28844446288     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2003-10-3446     Document Type: Article

References (50)

1. Robison LL. Down syndrome and leukemia. Leukemia. 1992;6:5-7.
2. Rosner F, Lee SL. Down's syndrome and acute leukemia: myeloblastic or lymphoblastic? report of forty-three cases and review of the literature. Am J Med. 1972;53:203-218.
3. Robison LL, Nesbit ME, Sather HN, et al. Down syndrome and acute leukemia in children: a 10-year retrospective survey from Children's Cancer Study Group. J Pediatr. 1984;105:235-242.
4. Fong CT, Brodeur GM. Down's syndrome and leukemia: epidemiology, genetics, cytogenetics and mechanisms of leukemogenesis. Cancer Genet Cytogenet. 1987;28:55-76.
5. Gaynon PS, Trigg ME, Heerema HA, et al. Children's Cancer Group trials in acute lymphoblastic leukemia: 1983-1995. Leukemia. 2000;14:2223-2233.
6. Pui CH, Boyett JM, Rivera GK, et al. Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia. 2000;14:2286-2294.
7. Schrappe M, Reiter A, Zimmermann M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981-1995: Berlin-Frankfurt-Munster. Leukemia. 2000;14:2205-2222.
8. Harms DO, Janka-Schaub GE. Co-operative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89, and 92. Leukemia. 2000;14:2234-2239.
9. Silverman LB, Declerck L, Gelber RD, et al. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). Leukemia. 2000;14:2247-2256.
10. Levitt GA, Stiller CA, Chessells JM. Prognosis of Down's syndrome with acute leukaemia. Arch Dis Child. 1990;65:212-216.
11. Kalwinsky DK, Raimondi SC, Bunin NJ, et al. Clinical and biological characteristics of acute lymphocytic leukemia in children with Down syndrome. Am J Med Genet Suppl. 1990;7:267-271.
12. Ragab AH, Abdel-Mageed A, Shuster JJ, et al. Clinical characteristics and treatment outcome of children with acute lymphocytic leukemia and Down's syndrome: a Pediatric Oncology Group study. Cancer. 1991;67:1057-1063.
13. Pui C-H, Raimondi SC, Borowitz MJ, et al. Immunophenotypes and karyotypes of leukemic cells in children with Down syndrome and acute lymphoblastic leukemia. J Clin Oncol. 1993;11:1361-1367.
14. Dördelmann M, Schrappe M, Reiter A, et al. Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials: Berlin-Frankfurt-Munster Group. Leukemia. 1998;12:645-651.
15. Chessells JM, Harrison G, Richards SM, et al. Down's syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment. Arch Dis Child. 2001;85:321-325.
16. Tubergen DG, Gilchrist GS, O'Brien RT, et al. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Children's Cancer Group phase III trial. J Clin Oncol. 1993;11:527-537.
17. Gaynon PS, Steinherz PG, Bleyer WA, et al. Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Childrens Cancer Group Study CCG-106. J Clin Oncol. 1993;11:2234-2242.
18. Hutchinson R, Neerhout R, Bertolone S, et al. Should therapy be intensified for patients with good risk ALL? [abstract] Blood. 1996;88:668a.
19. Lange BJ, Blatt J, Sather HN, Meadows AT. Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: a Childrens Cancer Group study. Med Pediatr Oncol. 1996;27:15-20.
20. Nachman J, Sather HN, Gaynon PS, Lukens JN, Wolff L, Trigg ME. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group. J Clin Oncol. 1997;15:2222-2230.
21. Uckun FM, Gaynon PS, Sensel MG, et al. Clinical features and treatment outcome of childhood Tlineage acute lymphoblastic leukemia according to the apparent maturational stage of T-lineage leukemic blasts: a Children's Cancer Group study. J Clin Oncol. 1997;15:2214-2221.
22. Bostrom B, Gaynon P, Sather H, et al. Dexamethasone (DEX) decreases central nervous system (CNS) relapse and improves event-free survival (EFS) in lower risk acute lymphoblastic leukemia (ALL) [abstract]. Proc Am Soc Clin Oncol. 1998;17:527a.
23. Steinherz PG, Gaynon PS, Breneman JC, et al. Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children's Cancer Group. Cancer. 1998;82:600-612.
24. Reaman GH, Sposto R, Sensel MG, et al. Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group. J Clin Oncol. 1999;17:445-455.
25. Lange B. The management of neoplastic disorders of haematopoiesis in children with Down's syndrome. Brit J Haematol. 2000;110:512-524.
26. Lange BJ, Bostrom BC, Cherlow JM, et al. Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 2002;99:825-833.
27. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996;14:18-24.
28. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
29. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient, II: analysis and examples. Brit J Cancer. 1977;35:1-39.
30. Collett D. Modelling Survival Data in Medical Research. London, United Kingdom: Chapman & Hall; 1994.
31. Ravindranath Y, Abella E, Krischer JP, et al. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Blood. 1992;80:2210-2214.
32. Lange BJ, Kobrinsky N, Barnard DR, et al. Distinctive demography, biology and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down Syndrome: Children's Cancer Group Studies 2861 and 2891. Blood. 1998;91:608-615.
33. Pui CH, Raimondi SC, Dodge RK, et al. Prognostic importance of structural chromosomal abnormalities in children with hyperdiploid (greater than 50 chromosomes) acute lymphoblastic leukemia. Blood. 1989;73:1963-1967.
34. Pui CH, Crist WM, Look AT. Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia. Blood. 1990;76:1449-1463.
35. Cline MJ. The molecular basis of leukemia. N Engl J Med. 1994;330:328-336.
36. Biondi A, Rambaldi A, Rossi V, et al. Detection of ALL-1/AF4 fusion transcript by reverse transcription-polymerase chain reaction for diagnosis and monitoring of acute leukemias with the t(4;11) translocation. Blood. 1993;82:2943-2947.
37. Shurtleff SA, Buijs A, Behm FG, et al. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia. 1995;9:1985-1989.
38. McLean TW, Ringold S, Neuberg D, et al. TEL/ AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood. 1996;88:4252-4258.
39. Lanza C, Volpe G, Basso G, et al. The common TEL-AML1 rearrangement does not represent a frequent event in acute lymphoblastic leukaemia occurring in children with Down syndrome. Leukemia. 1997;11:820-821.
40. Taub JW, Matherly LH, Stout ML, Buck SA, Gurney JG, Ravindranath Y. Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia. Blood. 1996;87:3395-3403.
41. Taub JW, Huang X, Matherly LH, et al. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Blood. 1999;94:1393-1400.
42. Blatt J, Albo V, Prin W, Orlando S, Wollman M. Excessive chemotherapy-related myelotoxicity in children with Down syndrome and acute lymphoblastic leukemia [letter]. Lancet. 1986;2:914.
43. Frankel LS, Pullen J, Boyett J, et al. Excessive drug toxicity in children with Down's syndrome (DS) treated for acute lymphocytic leukemia (ALL) despite similarity of clinical and biological features to other patients [abstract]. Proc Am Soc Clin Oncol. 1986;5:161.
44. Garré ML, Relling MV, Kalwinsky D, et al. Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia. J Pediatr. 1987;111:606-612.
45. Peeters M, Poon A. Down syndrome and leukemia: unusual clinical aspects and unexpected methotrexate sensitivity. Eur J Pediatr. 1987;146:416-422.
46. Gregory L, Williams R, Thompson E. Leucocyte function in Down's syndrome and acute leukaemia. Lancet. 1972;1:1359-1361.
47. Spina CA, Smith D, Korn E, Fahey JL, Grossman HJ. Altered cellular immune functions in patients with Down's syndrome. Am J Dis Child. 1981;135:251-255.
48. Freeman SB, Taft LF, Dooley KJ, et al: Population-based study of congenital heart defects in Down Syndrome. Am J Med Genet. 1998;80:213-217.
49. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999;286:531-537.
50. Armstrong SA, Staunton JE, Silverman LB, et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet. 2002;30:41-47.